Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|August 7, 2018
Make Compliance a Competitive Advantage
Author(s)Thermo Fisher
Are you looking to ensure compliance to the latest demanding regulations? Do need to be able to easily demonstrate control of your data? With Thermo Scientific™ Chromeleon™ CDS software you can rest assured. Delivering a comprehensive set of compliance tools,
Advertisement
Are you looking to ensure compliance to the latest demanding regulations? Do you need to be able to easily demonstrate control of your data? With Thermo Scientific™ Chromeleon™ CDS software you can rest assured. Delivering a comprehensive set of compliance tools, sequence-level data organization, and with audit trails tracking all actions in the software - including CDS-related external events – Chromeleon software allows you to defend your data with ease and utmost confidence, allowing you to focus on the important work of your lab.
From workstation to global deployment, Chromeleon software delivers compliance across your chromatography operation and throughout your enterprise − from research to routine quality testing − connecting people, instruments and other laboratory software, while delivering proven productivity gains for faster return on investment.
Email: kris.ben-jamin@thermofisher.com
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement